Companies › Alumis
1 active drug program in 3 registered trials: 2 Phase 2, 1 Phase 3; Immunology; next expected readout Sep 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Envudeucitinib (ESK-001) Oral PROTAC degrader of Ikaros (IKZF1) | IKZF1, TYK2 | Phase 3 | Plaque Psoriasis; SLE | Sep 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05966480 | Envudeucitinib (ESK-001) | Phase 2 | SLE | Immunology | Sep 2027 |
| NCT05739435 | Envudeucitinib (ESK-001) | Phase 2 | Plaque Psoriasis | Immunology | Dec 2027 |
| NCT06846541 | Envudeucitinib (ESK-001) | Phase 3 | Plaque Psoriasis | Immunology | Nov 2028 |
Cash and short-term investments of $502m on 2026-06-30; operating cash outflow about $342m a year; runway about 18 months at that burn, to Dec 2027; 2 of 3 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
Savara Alfasigma Quoin Pharmaceuticals Pharvaris Netherlands AUG Therapeutics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.